Daewoong Pharmaceutical introduced its fat-dissolving injection V-OLET at China’s largest aesthetics and plastic surgery congress, marking the company’s first major step toward expanding the product globally.

The company said it held the “V-OLET Scientific Forum” on Oct. 17 during Aesthetic & Anti-aging Medicine World Congress (AMWC) China 2025 in Chengdu, where it presented clinical data, differentiating features, and treatment cases for V-OLET to medical professionals from China and overseas.

V-OLET, launched in Korea in 2021, is a deoxycholic acid based fat-dissolving injection. It is the only product in Korea supported by a large-scale phase 3 clinical trial involving more than 960 participants, together with post-marketing studies verifying its safety and efficacy.

Interest in the product has been rising as the micro beauty trend grows among patients seeking refined contouring of localized areas such as the submental region and upper arms after GLP-1 induced weight loss from medicines such as Wegovy and Mounjaro.

With its mechanism of permanent fat destruction and collagen stimulation, V-OLET has gained attention for its ability to deliver precise and durable line correction.

AMWC China 2025 brought together more than 200 speakers, including clinicians from across China, and more than 200 participating companies. Daewoong Pharmaceutical said the scientific forum and booth activities served as a foothold for expanding V-OLET into global markets.

During the forum, Hang Wang, professor of plastic surgery at Sichuan University and an AMWC China executive committee member, delivered opening remarks highlighting trends in China’s fat-dissolving market and V-OLET’s differentiating strengths.

Ko Beom-joon, director of Doctor's Dermatology Clinic Sinsa in Seoul, presented results from Korea’s phase 3 study along with patient cases, emphasizing V-OLET’s effectiveness and safety based on years of accumulated clinical experience.

Li Xue, director of ARSMO Hainan, also joined as a speaker and drew strong interest from local clinicians.

Yoon Jun-soo, head of the Nabota Business Division at Daewoong Pharmaceutical, said the event represented V-OLET’s first step toward global expansion.

“V-OLET’s potential was recognized by both Korean and international clinicians, and we expect it to become a blockbuster brand leading Daewoong Pharmaceutical’s global medical aesthetics portfolio together with Nabota,” he said.